StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)

Close on Nov 17, 2026Market cap $36.53MP/E –Yield –

Caribou Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Caribou Biosciences's price to sales ratio was 4.1× on Nov 11, 2026, against 19.5× a year earlier. Over the last 5 years it ranged from 4.1× to 112.9×, with a median of 17.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.1×−11.9
2025Dec 31, 202516.0×+3.4
2024Dec 31, 202412.5×−2.1
2023Dec 29, 202314.6×−15.5
2022Dec 30, 202230.1×−82.8
2021Dec 31, 2021112.9×–

More Caribou Biosciences figures

See a number that looks wrong?